Log in to save to my catalogue

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2439673508

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

Publication information

Publisher

Boston: Massachusetts Medical Society

More information

Scope and Contents

Contents

MET
is altered by skipping exon 14 or gene amplification in 1 to 2% of patients with non–small-cell lung cancer. Capmatinib, a
MET
-specific tyrosine kinase inhibitor, led to a response in 40% of previously treated patients and in 67% of previously untreated patients whose tumors had
MET
alterations, with a median response duration o...

Alternative Titles

Full title

Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2439673508

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2439673508

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2002787

How to access this item